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Background:  Psoriasis is an inflammatory skin disease characterized by dermal infiltration of activated T cells and macrophages. These cells have 
been associated with cardiometabolic disease mediated through inflammatory pathways. We evaluated the skin and serum to establish whether 
dysregulation of common pathways link psoriasis to these comorbidities.
Methods:  Microarray analyses (Affymetrix U133+2 array) were completed on skin biopsies from a subset of the ACCEPT trial, a randomized trial 
in 903 psoriasis patients (n=85 pts for baseline lesional and nonlesional skin); 25 healthy skin biopsies were used for comparison of lesional and 
nonlesional skin to healthy skin. Serum (n=145) was tested at baseline for a panel of 91 proteins including cytokines and chemokines (monocyte 
chemoattractant protein-1, MCP-1; CCL22) using a Luminex-based platform (Rules Based Medicine Human MAP).
Results:  Microarray analyses at baseline showed several probesets differentially expressed (>2-fold change, FDR p<0.05) in lesional skin 
compared to healthy, control skin. We found significant changes in gene expression in the skin for the chemokines MCP-1 and CCL22 (> 6-fold 
change lesional vs healthy, p<0.00001). LXR-alpha, a well known, protective lipoprotein metabolism gene, showed a 6-fold decrease in lesional vs 
healthy skin (p<0.00001) while PPAR-alpha, an insulin-sensitizing gene showed a 7-fold decrease (p<0.00001). Serum testing revealed proteins 
associated with the genes MCP-1 and CCL22 were elevated in psoriasis (mean MCP-1 502 pg/ml psoriasis vs 141 pg/ml healthy; CCL22 1240 pg/
ml vs 409 pg/ml (p<0.00001). Dysregulated lipid metabolism was also evident in the serum, as Apo-A1, the main protein in HDL and linked to PPAR-
alpha function, was significantly decreased in psoriasis compared to controls (252 ug/ml vs 389 ug/ml, respectively, p< 0.00001).
Conclusions:  Skin and serum analyses in psoriasis identified dysregulated inflammatory (MCP-1 and CCL22) and lipid metabolism (LXR-a, 
PPAR-a) pathways in psoriasis. This provides evidence of a potential shared pathophysiology linking psoriasis to cardiometabolic disease, however 
larger studies will be needed to confirm these findings.
